Brenus Pharma Wins French Tech Saint-Etienne Lyon's BIG Start-up of the Year Award
July 03 2024 - 4:12AM
Business Wire
During its annual event "BIG UP", French Tech Saint-Etienne Lyon
awarded the BIG Start-up of the Year trophy, honoring a start-up
that exemplifies the region's innovation and richness.
French Tech Saint-Etienne Lyon, a non-profit association
established in 2015, promotes the creation, growth, and
internationalization of innovative companies in Lyon and
Saint-Étienne.
Designated as one of the 17 French Tech Capitals by the French
government until 2026, it follows the roadmap of La Mission French
Tech under the Ministry of Economy, integrating the Lyon St Étienne
region into a network of over 100 French Tech Communities across
five continents.
French Tech Capitals and Communities serve as entry points for
French start-ups into the global French Tech ecosystem.
On June 17, during the French Tech Saint-Etienne Lyon board
meeting, which included founders and CEOs of local start-ups and
innovation stakeholders like incubators, clusters, and large
corporations, Brenus Pharma was named BIG Start-up of the Year.
"By winning this award, Brenus Pharma stood out among 12
shortlisted candidates, meeting criteria of innovation and positive
impact on our territory. We are proud to have Brenus Pharma among
our members, now recognized as a promising player in our network,
perfectly reflecting the values of La Mission French Tech," said
Lucie Texier, General Delegate of French Tech Saint-Etienne
Lyon.
About French Tech Saint-Etienne Lyon: Alongside actors
supporting innovation, French Tech Saint-Etienne Lyon unites and
animates the local ecosystem. It contributes to environmental and
social transitions for a sustainable and inclusive innovation and
entrepreneurship territory. The association has over 539 members,
including 475 start-ups and 64 public and private partners.
About Brenus Pharma : Brenus Pharma is a French biotech
developing a pioneering discovery platform, Stimulated-Tumor-Cell
(STC), leading the way to a new generation of therapeutic cancer
vaccines.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240703702575/en/
Marion BRUN contact@brenus-pharma.com